The documentation your insurer typically wants includes a recorded BMI meeting the threshold (30 or above, or 27 with comorbidities), proof of at least one qualifying comorbidity, evidence of previous weight loss attempts (usually 3-6 months of documented lifestyle intervention), current lab work showing relevant metabolic markers, and a letter of medical necessity from your prescribing physician
Hadidchis expertise can guide you toward achieving a healthier lifestyle
This research-backed guide explains why semaglutide-related weight gain happens, summarizes the best evidence, and gives you a practical plan to use with your care team
Key Findings from Phase 2 Trials and the Phase 3 Programme Phase 2 data showed approximately 24% mean body weight reduction at the highest dose over 48 weeks
They can offer guidance on whether the vial should be discarded or if it is still safe to inject
This is the most frequently reported effect and is inherent to GHRP-6's mechanism Mild water retention and peripheral edema, particularly during the first 2 to 4 weeks Transient flushing, warmth, or dizziness immediately post-injection Injection site reactions (redness, minor swelling) Less Common: Tingling or numbness in the extremities (hands and feet), related to GH-mediated fluid shifts Head rush or lightheadedness shortly after administration Drowsiness, particularly with evening doses Dose-Dependent (above saturation dose): Elevated cortisol via ACTH stimulation